Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials

The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.